Chronic Myelogenous Leukemia — New Concepts
Generate an AI Snapshot to get a quick, structured summary of this paper.
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
A large number of patients diagnosed with chronic myelogenous leukemia with a marked prophylactic response to chemotherapy also have a history of atypical Irving's disease.
Abstract
CHRONIC myelogenous leukemia (CML) is a clonal myeloproliferative disorder arising from neoplastic transformation at the level of the pluripotent stem cell and characterized clinically by a marked overproduction of granulocytes. The disease was probably first identified in 1845 by Craigie,1 Bennett,2 and Virchow,3 who called attention to the prominent splenomegaly and "suppuration of the blood." In 1960, Nowell and Hungerford described an abnormal, small chromosome (the Philadelphia, or Ph1, chromosome) in patients with this disorder.4 Because of the typical clinical picture and the specific chromosomal abnormality, CML is perhaps the best defined of the myeloproliferative disorders. In western countries, . . .
